Abstract
Background: Alzheimer’s Disease (AD) is still a great global challenge and agents with various mechanisms represent a promising therapeutic opportunity. Theracurmin, a very highly absorbable curcumin formulation, was shown to improve memory and attention in non-demented people.
Objective: The aim of the study was to investigate the effect of Theracurmin on disease course in elderly patients with mild cognitive impairment (MCI) and AD.
Methods: This follow-up study was performed retrospectively on 93 patients with MCI or AD. All patients underwent comprehensive geriatric assessment, including Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), clock-drawing test, activities of daily living (ADL), at baseline and at the end of the 6th month. 19 patients with AD and 17 with MCI were treated with Theracurmin 180 mg/day per oral.
Results: MMSE, MOCA and instrumental ADL scores decreased in AD patients not treated with Theracurmin (p<0.001, p=0.011, and p=0.004, respectively), whereas these scores remained stable in those treated with Theracurmin. This stabilization in the instrumental ADL was also observed in MCI patients treated with Theracurmin. During the follow-up, three MCI patients who did not receive Theracurmin progressed to AD, whereas only one patient progressed in those who received it.
Conclusion: Theracurmin seems to be a therapeutic option for elderly patients with AD and MCI via providing stabilization of the disease course by preventing progressive loss in cognitive functions and ADLs.
Keywords: Acetylcholinesterase inhibitors, Alzheimer’s disease, elderly, theracurmin, curcumin, mild cognitive impairment.
Current Alzheimer Research
Title:Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer’s Disease: A 6-Month Retrospective Follow-Up Study
Volume: 18 Issue: 14
Author(s): Fatma Sena Dost, Derya Kaya, Mehmet Selman Ontan, Neziha Erken, Esra Ateş Bulut, Ali Ekrem Aydin and Ahmet Turan Isik*
Affiliation:
- Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir,Turkey
Keywords: Acetylcholinesterase inhibitors, Alzheimer’s disease, elderly, theracurmin, curcumin, mild cognitive impairment.
Abstract:
Background: Alzheimer’s Disease (AD) is still a great global challenge and agents with various mechanisms represent a promising therapeutic opportunity. Theracurmin, a very highly absorbable curcumin formulation, was shown to improve memory and attention in non-demented people.
Objective: The aim of the study was to investigate the effect of Theracurmin on disease course in elderly patients with mild cognitive impairment (MCI) and AD.
Methods: This follow-up study was performed retrospectively on 93 patients with MCI or AD. All patients underwent comprehensive geriatric assessment, including Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), clock-drawing test, activities of daily living (ADL), at baseline and at the end of the 6th month. 19 patients with AD and 17 with MCI were treated with Theracurmin 180 mg/day per oral.
Results: MMSE, MOCA and instrumental ADL scores decreased in AD patients not treated with Theracurmin (p<0.001, p=0.011, and p=0.004, respectively), whereas these scores remained stable in those treated with Theracurmin. This stabilization in the instrumental ADL was also observed in MCI patients treated with Theracurmin. During the follow-up, three MCI patients who did not receive Theracurmin progressed to AD, whereas only one patient progressed in those who received it.
Conclusion: Theracurmin seems to be a therapeutic option for elderly patients with AD and MCI via providing stabilization of the disease course by preventing progressive loss in cognitive functions and ADLs.
Export Options
About this article
Cite this article as:
Dost Sena Fatma , Kaya Derya , Ontan Selman Mehmet , Erken Neziha , Bulut Ateş Esra , Aydin Ekrem Ali and Isik Turan Ahmet*, Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer’s Disease: A 6-Month Retrospective Follow-Up Study, Current Alzheimer Research 2021; 18 (14) . https://dx.doi.org/10.2174/1567205019666211221125255
DOI https://dx.doi.org/10.2174/1567205019666211221125255 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain
CNS & Neurological Disorders - Drug Targets Epigenetics and the Environmental Regulation of the Brain's Genome and its Function
Current Psychiatry Reviews Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease
Current Medicinal Chemistry Implications of Prion Protein Biology
Current Neurovascular Research Blood-Brain Interfaces and Bilirubin-Induced Neurological Diseases
Current Pharmaceutical Design Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Profiling of Enzymatic Activities Using Peptide Arrays
Mini-Reviews in Organic Chemistry Cingulate Volume Abnormalities in Emerging Psychosis
Current Pharmaceutical Design SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry The Clinical and Biological Relationship between Type II Diabetes Mellitus and Alzheimers Disease
Current Alzheimer Research C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome
Current Alzheimer Research Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Current Medicinal Chemistry Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
CNS & Neurological Disorders - Drug Targets A Simple Technique to Establish a Long-Term Adenovirus Mediated Gene Transfer to the Heart of Newborn Mice
Cardiovascular & Hematological Disorders-Drug Targets Molecular and Cellular Mechanisms in the Pathophysiology of Severe Head Injury
Current Pharmaceutical Design Neurosarcoidosis
Current Neuropharmacology